Results 171 to 180 of about 5,420 (200)

Atropine/cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide

Reactions weekly, 2022

semanticscholar   +1 more source

Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide

Reactions Weekly, 2022
openaire   +2 more sources

Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network

Clinical Infectious Diseases, 2020
John Lambert, David Bürger, Angela Colbers   +2 more
exaly  

Dolutegravir/elvitegravir/raltegravir

Reactions Weekly, 2017
openaire   +1 more source

Changes in neurocognitive assessment scores after initiating dolutegravir- versus elvitegravir-based antiretroviral therapy

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021
Laura Pontiggia, John Baxter, Jessica Adams   +2 more
exaly  

Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data

International Journal of STD and AIDS, 2021
Sibel Bolukcu, Fehmi Tabak, Bilgul Mete   +2 more
exaly  

Dolutegravir/elvitegravir/raltegravir

Reactions Weekly, 2019
openaire   +1 more source

The development and application of a novel LC–MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016
Emilie Elliot, Sujan Dilly Penchala, Marta Boffito   +2 more
exaly  

ELVITEGRAVIR /

2014
openaire   +1 more source

Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines

Antiviral Research, 2016
Marta Giralt, Joan Carles Domingo Pedrol, Joan Villarroya   +2 more
exaly